Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that Dapagliflozin, as a highly selective SGLT-2 inhibitor,38 may have the ability to influence the function of central autonomic control that results in neural activation related to BP and HR regulation.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [38]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Kidney: Physiology and Pathophysiology
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-544_3 · Cited by 1,673
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Research works printed but not linked: 17
- Washburn W., 2007, 234th National ACS Meeting
- 2006, Diabetes Atlas
- Bertoni A. G., 2007, Diabetes Care
- Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199
- Moe O. W., 2000, The Kidney, 375
- Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229
- Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201
- Wells R. G., 1992, Am. J. Physiol., 263, F459
- Santer R., 2000, J. Inher. Metab. Dis., 23, 178
- 2004, Chem. Abstr., 142, 94061
- 2004, Chem. Abstr., 141, 332411
- 2004, Chem. Abstr., 141, 123854
- 2003, Chem. Abstr., 138, 153771
- 2001, Chem. Abstr., 135, 273164
- 2001, Chem. Abstr., 135, 273163
- 2003, Chem. Abstr., 138, 221784
- 2004, Chem. Abstr., 141, 89317
Cited by
Items 301–400 of 684
Mishra, L. K., Sarkar, D., Mentreddy, S. R., & Shetty, K. (2019) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2019.100310 · Cited by 20
Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway
Arad, M., Waldman, M., Abraham, N. G., & Hochhauser, E. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106454 · Cited by 21
Nugrahaningrum, D. A., Marcelina, O., Liu, C., Wu, S., & Kasim, V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01104 · Cited by 20
“Dapagliflozin is the first SGLT2 inhibitor used for antihyperglycemia therapy licensed by the FDA in 2014 (Meng et al., 2008; Saeed and Narendran, 2014).”
BackgroundLv, B., Feng, Y., Dong, J., Xu, M., Xu, B., Zhang, W., Sheng, Z., Welihinda, A. A., Seed, B., & Chen, Y. (2010) · ChemMedChem · doi:10.1002/cmdc.201000051 · Cited by 21
SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
Tamez-Pérez, H. E., Delgadillo-Esteban, E., Soni-Duque, D., Hernández-Coria, M. I., & Tamez-Peña, A. L. (2017) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-017-0308-4 · Cited by 19
Kowalska, K., Wilczopolski, P., Buławska, D., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · Antioxidants · doi:10.3390/antiox11122500 · Cited by 23
“Florisin use has been limited due to poor intestinal absorption and numerous side effects, yet it was the lead compound in understanding the physiology of SGLT and designing research on modern drugs targeting SGLT2 receptors [30,31].”
Lin, T.-S., Liw, Y., Song, J., Hsieh, T.-C., Yeh, A. H.-W., Hsu, L., Lin, C., Wu, S., & Liang, P. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.067 · Cited by 21
Imamura, A., Kusunoki, M., Ueda, S., Hayashi, N., & Imai, Y. (2013) · Diabetes Therapy · doi:10.1007/s13300-012-0016-5 · Cited by 19
“Dapagliflozin is a first-in-class selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of T2DM that improves glycemic control by reducing the reabsorption of glucose in the kidney and enhancing the urinary excretion of excess glucose [8, 9].”
BackgroundXu, J., Yuan, H., Ran, T., Zhang, Y., Liu, H., Lü, S., Xiong, X., Xu, A., Jiang, Y., Lu, T., et al. (2015) · Journal of Molecular Recognition · doi:10.1002/jmr.2464 · Cited by 19
“…AstraZeneca (London, UK) and Bristol-Myers Squibb (New York City, NY, USA), is the first SGLT2 antagonist approved for marketing in Europe in April 2012 with approximately 1200 times more selective for SGLT2 (EC50 = 1.1 nM) than SGLT1 (EC50 = 1390 nM) (Hanefeld and Forst, 2010; Meng et al., 2008).”
BackgroundInfluentialA Strategy for the Synthesis of Anthraquinone-Based Aryl-C-glycosides
Anand, N., Upadhyaya, K., Ajay, A., Mahar, R., Shukla, S. K., Kumar, B. N., & Tripathi, R. P. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo302589t · Cited by 19
Lee, S., Kim, M. J., Lee, S.-H., Kim, J., Park, H., & Lee, J. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.052 · Cited by 19
Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design
Cao, X., Zhang, W., Yan, X., Huang, Z., Zhang, Z., Wang, P., & Shen, J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.065 · Cited by 19
Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00028-4 · Cited by 18
Self-citationAn Overview on Glyco-Macrocycles: Potential New Lead and their Future in Medicinal Chemistry
Singh, K., & Tripathi, R. P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190227232721 · Cited by 18
Mishra, N., Tiwari, V. K., & Schmidt, R. R. (2020) · Carbohydrates in Drug Discovery and Development · doi:10.1016/b978-0-12-816675-8.00001-4 · Cited by 17
Bellanca, C. M., Augello, E., Benedetto, G. D., Burgaletto, C., Cantone, A. F., Cantarella, G., Bernardini, R., Polosa, R., & the DiaSmokeFree Working Group (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406860 · Cited by 17
Unveiling the Stereoselectivity Aspects of Metallaphotoredox Decarboxylative Arylation
Nallagonda, R., Quan, R., Grant, L. N., Jorge, C., Yip, S. H., Wu, D., Dhar, T. G. M., Kempson, J., Mathur, A., & Oderinde, M. S. (2024) · ACS Catalysis · doi:10.1021/acscatal.4c03818 · Cited by 17
[Modification of natural products for drug discovery].
Guo, Z. (2012) · PubMed · Cited by 17
Ohba, K., Koga, Y., Nomura, S., & Nakata, M. (2015) · Tetrahedron Letters · doi:10.1016/j.tetlet.2015.01.054 · Cited by 17
Castaneda‐Sceppa, C., & Castañeda, F. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00423.x · Cited by 20
Yuan, M.-C., Yeh, T., Chen, C., Song, J., Huang, Y., Hsieh, T.-C., Huang, C.-Y., Huang, Y., Wang, M., Wu, S., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.019 · Cited by 17
Tang, W., Reele, S. B., Hamer-Maansson, J. E., Parikh, S. J., & de Bruin, T. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12425 · Cited by 17
“Dapagliflozin is an orally active, highly selective, reversible sodium glucose cotransporter 2 (SGLT2) inhibitor [1] that inhibits renal glucose reabsorption, resulting in increased glucose excretion [2].”
BackgroundHrapchak, M. J., Latli, B., Wang, X., Lee, H., Campbell, S. J., Song, J. J., & Senanayake, C. H. (2014) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3240 · Cited by 21
Zhang, Y., Xie, P., Li, Y., Chen, Z., & Shi, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142003 · Cited by 16
“Sustained hyperglycemia can lead to systemic microvascular and macrovascular changes, resulting in various complications (Meng et al., 2008).”
BackgroundBarakat, E. H., Kassem, A. M., Ibrahim, M. F., Elsayad, M. K., Abdelgawad, W. Y., Salama, A., Alruwaili, N. K., Alsaidan, O. A., & Elmowafy, M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105804 · Cited by 16
Typical Cases of Continuous Flow Chemistry in Pharmaceutical Synthesis in 2023–2024
Feng, K., Zhu, Y., Gu, S., Long, J., & Wang, H. (2025) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202500132 · Cited by 20
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time
Parikh, S. J., Wilding, J. P. H., Jabbour, S. A., & Hardy, E. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12531 · Cited by 16
Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors
Kang, S. Y., Kim, M. J., Lee, J. S., & Lee, J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.063 · Cited by 16
Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
Din, U. A. S. E., Salem, M. M., & Abdulazim, D. O. (2021) · Nefrología (English Edition) · doi:10.1016/j.nefro.2021.03.014 · Cited by 18
Ramani, J., Shah, H., Vyas, V. K., & Sharma, M. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100074 · Cited by 23
Wei, P., Zhang, D., Gao, Z., Cai, W., Xu, W., Tang, L., & Zhao, G. (2015) · Synthetic Communications · doi:10.1080/00397911.2015.1005630 · Cited by 16
Li, Z., Xu, X. J., Deng, L., Liao, R., Liang, R., Zhang, B., & Zhang, L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.017 · Cited by 16
Kuroda, S., Kobashi, Y., Oi, T., Kawabe, K., Shiozawa, F., Okumura-Kitajima, L., Sugisaki-Kitano, M., Io, F., Yamamoto, K., & Kakinuma, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.12.015 · Cited by 16
Jabbour, S. A., Whaley, J. M., Tirmenstein, M. A., Poucher, S. M., Reilly, T. P., Boulton, D. W., Saye, J. A., List, J. F., & Parikh, S. J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2569 · Cited by 16
Self-citationKurahayashi, K., Hanaya, K., Sugai, T., Hirai, G., & Higashibayashi, S. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202203376 · Cited by 19
Synthesis of 1,2-Disubstituted C-Aryl Glycosides via Palladium/Norbornene Cooperative Catalysis
Zhao, P., Li, L., Shi, F., Su, Y., Lv, T., Huo, X., & Wang, X. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c01491 · Cited by 15
Agunloye, M. O., Owu, D. U., Onaadepo, O., Bisong, S. A., Ogunyemi, O. M., & Ugwu, F. N. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01551-y · Cited by 15
Ohtake, Y., Sato, T., Matsuoka, H., Kobayashi, T., Nishimoto, M., Taka, N., Takano, K., Yamamoto, K., Ohmori, M., Higuchi, T., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.053 · Cited by 15
de Bruin, T. W., Reele, S. B., Hamer-Maansson, J. E., Parikh, S. J., & Tang, W. (2015) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.220 · Cited by 16
“Dapagliflozin is a selective and reversible inhibitor of sodium-glucose cotransporter 2, the main glucose transporter in the renal proximal tubule.(11,12,18) Dapagliflozin reduces hyperglycemia, body weight, and blood pressure, and was well tolerated in numerous clinical trials when taken alone as well as in combinati…”
BackgroundSixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?
Clapham, J. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9882-1_1 · Cited by 19
Kong, Y., Song, K., Jung, M. E., Kang, M., Kim, H. J., & Kim, M. J. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128466 · Cited by 16
Advances in the Synthesis of Natural Products and Medicinally Relevant Molecules from Glycals
Hussain, N., Rasool, F., Khan, S., Saleem, M., & Maheshwari, M. (2022) · ChemistrySelect · doi:10.1002/slct.202201873 · Cited by 15
SGLT2 Inhibitors for Type 2 Diabetes
Liu, J., & Lee, T. W. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00020-5 · Cited by 15
Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
Du, X., Lizarzaburu, M. E., Turcotte, S., Lee, T. W., Greenberg, J., Shan, B., Fan, P. W., Ling, Y., Medina, J. C., & Houze, J. B. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.053 · Cited by 16
Dapagliflozin: an emerging treatment option in type 2 diabetes
Kipnes, M. S. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766794 · Cited by 15
“1 Chemistry Dapagliflozin is a C-aryl glucoside-derived SGLT2 inhibitor (Figure 1), which, unlike O-glucoside SGLT2 inhibitors such as remogliflozin or AVE2268 (Table 1), is resistant to gastrointestinal β-glucosidase enzymes and, therefore, can be administered orally in an unmodified form [14].”
BackgroundInfluentialType 2 Diabetes Mellitus- Disease, Diagnosis and Treatment
Xu, Y. Z. G. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000533 · Cited by 20
“The SGLT2 inhibitors like dapagliflozin are highly selective SLGT2-inhibitors and reduce reabsorption of glucose in the kidney [39].”
BackgroundSynthesis of Benzyl C‐Analogues of Dapagliflozin as Potential SGLT2 Inhibitors
Mukkamala, R., Kumar, R., Banerjee, S., & Aidhen, I. S. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202000025 · Cited by 26
Chu, K.-F., Song, J., Chen, C., Yeh, T., Hsieh, T.-C., Huang, C.-Y., Wang, M., Wu, S., Yao, C., Chao, Y., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.006 · Cited by 15
An efficient method for synthesis of bexagliflozin and its carbon-13 labeled analogue
Xu, G. Z., Xu, B., Song, Y., & Sun, X. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.09.003 · Cited by 14
Rethinking Carbohydrate Synthesis: Stereoretentive Reactions of Anomeric Stannanes
Zhu, F., O’Neill, S., Rodriguez, J., & Walczak, M. A. A. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201803082 · Cited by 15
Xu, G., Du, F., Kuo, G., Xu, J. Z., Liang, Y. T., Demarest, K. T., & Gaul, M. D. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127387 · Cited by 17
Optimization and Scale-Up of a Continuous Flow Synthesis of Dapagliflozin
Wang, C., Xuan, B., Huang, C., Yao, J., Wu, C., & Sun, T. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00389 · Cited by 14
Kuroda, S., Kobashi, Y., Oi, T., Amada, H., Okumura-Kitajima, L., Io, F., Yamamto, K., & Kakinuma, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.035 · Cited by 14
Busse, D., Tang, W., Scheerer, M. F., Danne, T., Biester, T., Sokolov, V., Boulton, D. W., & PARKINSON, J. R. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13981 · Cited by 14
“Dapagliflozin is a potent, highly selective and orally active inhibitor of the human renal sodium‐glucose cotransporter type‐2 (SGLT2), the major transporter responsible for renal glucose reabsorption.(6) Dapagliflozin lowers plasma glucose by inhibiting the renal reabsorption of glucose, thereby promoting its urinary…”
BackgroundBioactive C-glycosides inspired from natural products towards therapeutics
Reddy, M. R., Thoti, N., & Aidhen, I. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816675-8.00003-8 · Cited by 16
Íbias, J., O’Dell, L. E., & Nazarian, A. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.018 · Cited by 14
Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
Oranje, P., Gouka, R. J., Burggraaff, L., Vermeer, M. A., Chalet, C., Duchateau, G. S. M. J. E., Pijl, P., Geldof, M., de Roo, N., Clauwaert, F., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.504 · Cited by 17
Frooman, M. B., Deb, M. K., Peters, J., Leggett, S., Sanghai, N., Rizvi, N. Z., Atukorallaya, D., & Tranmer, G. K. (2025) · Pharmaceuticals · doi:10.3390/ph18121798 · Cited by 16
Ding, H., Zhang, X.-L., Guo, A., Lee, Q. P., Cai, C., Li, M., Cao, H., & Liu, X. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00537 · Cited by 13
Aidhen, I. S., & Thoti, N. (2021) · The Chemical Record · doi:10.1002/tcr.202100216 · Cited by 13
Stereoselective Palladium-Catalyzed Arylation of Exo-Glycals with Aryl Iodides
Regier, J., Ghanty, S., & Bolshan, Y. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c02533 · Cited by 13
Maideen, N. M. P., Balasubramanian, R., & Muthusamy, S. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220401092112 · Cited by 13
Ruthenium-Catalyzed Pyridine-Directed Aryl C–H Glycosylation with Glycosyl Chlorides
Cai, S., Sun, Q., Wang, Q., He, G., & Chen, G. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c00815 · Cited by 13
Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00027-4 · Cited by 16
Self-citationKeller, J. P., & Looger, L. L. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.001 · Cited by 13
“To ensure that this was Sglt2-specific and not an artifact induced by variations in buffer contents, the Sglt2 inhibitor dapagliflozin (EC50 1.1 nM [Meng et al., 2008]) was added at 500 nM.”
BackgroundInfluentialPlants: Revamping the Oldest Source of Medicines with Modern Science
Appendino, G., & Pollastro, F. (2009) · Royal Society of Chemistry eBooks · doi:10.1039/9781847559890-00140 · Cited by 14
origins of type 2 diabetes medications
Bailey, C. J. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.388 · Cited by 12
Zhang, J., Chen, X., Lv, S., & Hao, Q. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317295 · Cited by 15
Osigwe, C. C., Akah, P. A., Nworu, C. S., Okoye, T. C., & Tchimene, M. K. (2015) · Pharmacology & Pharmacy · doi:10.4236/pp.2015.611054 · Cited by 12
“Similarly, dapagliflozin, a potent SGLT-2 inhibitor caused a dose dependent reduction in blood glucose level by as much as 60% in STZ-induced diabetic rats over a 5-hr period following oral administration [87].”
BackgroundReagent-Controlled Divergent Synthesis of C-Glycosides
Han, P., Liu, J., Liao, J., Tu, Y., & Sun, J. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01544 · Cited by 12
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Lukic, N., Mačvanin, M., Gluvic, Z. M., Rizzo, M., Radak, D. J., Suri, J. S., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673251493231011192520 · Cited by 16
Stereoselective strain-release Ferrier rearrangement: the dual role of catalysts
Zhang, H., Guo, A., Ding, H., Xu, Y., Zhang, Y., Yang, D., & Liu, X. (2024) · Organic Chemistry Frontiers · doi:10.1039/d4qo00410h · Cited by 12
The pharmacological treatment of obesity: Past, present and future
Simonyi, G., Pados, G., Medvegy, M., & Bedros, J. R. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29317 · Cited by 16
Nauck, M. A., Prato, S. D., Meier, J. J., Durán-Garcia, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2013) · PubMed · doi:10.1055/s-0032-1305283 · Cited by 12
Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2
Park, E., Kong, Y., Lee, J. S., Lee, S.-H., & Lee, J. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.115 · Cited by 12
Yu, H. J., & Woo, V. C. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s117982 · Cited by 12
“SGLT2s are almost exclusively found in the S1 segment of the proximal renal tubules.(59,60) In rodent studies and in healthy individuals, they have been shown to reabsorb ~90% of the average 180 g filtered glucose, with the SGLT1s in the distal proximal tubules reabsorbing the remainder.”
Rico-Fontalvo, J. E., Daza-Arnedo, R., Cardona-Blanco, M., Leal-Martínez, V., Abuabara-Franco, E., Pájaro-Galvis, N., Cabrales, J., Correa, J., Cueto, M., Amable, D., et al. (2020) · Journal of Clinical Nephrology · doi:10.29328/journal.jcn.1001058 · Cited by 14
Design and synthesis of fluorescent SGLT2 inhibitors
Lansdell, M. I., Burring, D. J., Hepworth, D., Strawbridge, M., Graham, E. J. S., Guyot, T., Betson, M. S., & Hart, J. D. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.036 · Cited by 12
Xu, G., Gaul, M. D., Kuo, G., Du, F., Xu, J. Z., Wallace, N. H., Hinke, S. A., Kirchner, T., Silva, J., Huebert, N. D., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.025 · Cited by 14
Sakolish, C., Tsai, H.-H. D., Lin, H.-C., Bajaj, P., Villenave, R., Ferguson, S. S., Stanko, J. P., Becker, R. A., Hewitt, P., Chiu, W. A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030563 · Cited by 11
“While Tenofovir is an OAT1 substrate [62], OAT1 plays no role in Dapagliflozin pharmacokinetics [64] because it is a P-gp substrate [65] and an SGLT2 (SLC5A2) inhibitor [66]. ciPTEC-OAT1 cells were also able to correctly predict Adefovir as a toxic compound.”
Dapagliflozin-Induced Acute-on-Chronic Liver Injury
Levine, J. A., Lo, A. A., Wallia, A., Rogers, M. C., & VanWagner, L. B. (2016) · ACG Case Reports Journal · doi:10.14309/crj.2016.142 · Cited by 11
Studies towards the synthesis of ertugliflozin from l-Arabinose
Triantakonstanti, V. V., Mountanea, O. G., Papoulidou, K.-E. C., Andreou, T., Koftis, T. V., & Gallos, J. K. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.08.005 · Cited by 12
Takuma, K., Fuchigami, A., Shigiyama, F., Kumashiro, N., & Hirose, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15089 · Cited by 12
“Sodium-glucose cotransporter-2 (SGLT2) inhibitors are oral antihyperglycaemic drugs that inhibit renal reabsorption and promote glycosuria, thereby causing an insulin-independent reduction in blood glucose level.(17) Furthermore, they decrease the risk factors for cardiovascular diseases, such as high body weight, adi…”
BackgroundRamping Glucosuria for Management of Type 2 Diabetes Mellitus: An Emerging Cynosure
Malla, P., Kumar, R., Mahapatra, M. K., & Kumar, M. (2014) · Medicinal Research Reviews · doi:10.1002/med.21314 · Cited by 11
Adawi, R. M. A., Jassim, Z., Elgaily, D. E., Abdelaziz, H., Sree, B., & Ibrahim, M. I. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-43052-6 · Cited by 12
Syntheses of SGLT2 Inhibitors by Ni- and Pd-Catalyzed Fukuyama Coupling Reactions
Talode, J. B., Kato, D., Nagae, H., Tsurugi, H., Seki, M., & Mashima, K. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01635 · Cited by 11
Polli, J. W., & Humphreys, J. E. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000200 · Cited by 16
A tool for multi-scale modelling of the renal nephron
Nickerson, D. P., Terkildsen, J. R., Hamilton, K. L., & Hunter, P. J. (2011) · Interface Focus · doi:10.1098/rsfs.2010.0032 · Cited by 11
The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective
Jiang, Y., Liu, P., Qiu, Z., Zhou, M., Cheng, M., & Yang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116593 · Cited by 11
Gliflozins in hypertension: basic mechanisms and clinical insights
Rieg, T., Liu, R., & Staruschenko, A. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00119.2025 · Cited by 10
The Impact of Continuous Flow Technology and Collaboration between Academia and Industry
Jamieson, P., Bannon, R., Cronly, D., Smyth, M., Wharry, S., Moody, T. S., Lennon, G., & Baumann, M. (2026) · JACS Au · doi:10.1021/jacsau.5c01617 · Cited by 13
Dapagliflozin – structure, synthesis, and new indications
Balkanski, S. V. (2021) · Pharmacia · doi:10.3897/pharmacia.68.e70626 · Cited by 10
Strategies for Managing Solid Form Transformation Risk in Drug Product
Kestur, U. S., Patel, A., Badawy, S. I. F., Mathias, N. R., & Zhang, L. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.12.002 · Cited by 10
Synthesis of SGLT2 Inhibitors by Means of Fukuyama Coupling Reaction
Seki, M., Tapkir, S. R., Nadiveedhi, M. R., Kalita, S. J., Mulani, S. K., & Mashima, K. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01873 · Cited by 10
Sanchez, R. A., Sanabria, H. D., Santos, C. D. L., & Ramirez, A. J. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i11.1186 · Cited by 10
Tsujita, M., Hossain, M. A., Lu, R., Tsuboi, T., Okumura-Noji, K., & Yokoyama, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.39156 · Cited by 7
Wang, X., Li, Y., Yang, B., Li, Z., Huang, W., & Qian, H. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12487 · Cited by 10
“Dapagliflozin (14,15) disclosed by Bristol–Myers Squibb Co and AstraZeneca is the first SGLT2 inhibitor approved by Euro-”
BackgroundSynthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors
Qi, Y., Ding, N., & Li, Y. (2015) · Carbohydrate Research · doi:10.1016/j.carres.2015.10.011 · Cited by 10
Wang, L., Wang, H., Liu, Q., Hua, W.-C., & Li, C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.002 · Cited by 10
Ertugliflozin for treatment of patients with Type 2 diabetes mellitus
Yang, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1503051 · Cited by 12
Metadata
- Authors
- Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., Zahler, R., Deshpande, P. P., Pullockaran, A., Hagan, D. L., Morgan, N., Taylor, J. R., Obermeier, M. T., Humphreys, W. G., Khanna, A., Discenza, L., Robertson, J. G., Wang, A., Han, S., Wetterau, J. R., Janovitz, E. B., Flint, O. P., Whaley, J. M., & Washburn, W. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Metabolic Diseases Chemistry, Process R & D, Metabolic Diseases Biology, Pharmacological Candidate Optimization, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543
- Corresponding author
- Meng, Wei
- Washburn, William N.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 5
- Pages
- 1145-1149
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2026609170
- Cited by
- 634
- References
- 39
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 28 · 2023: 23 · 2022: 35 · 2021: 32 · 2020: 40 · 2019: 34 · 2018: 26 · 2017: 22 · 2016: 35 · 2015: 44 · 2014: 40 · 2013: 36 · 2012: 43
- FWCI
- 35.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, antidiabetic drug discovery, blood glucose reduction, streptozotocin-induced hyperglycemia, ADME properties
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Humans, Hypoglycemic Agents, Kidney, Stereoisomerism, Sodium-Glucose Transporter 2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.